logo-loader
viewAchieve Life Sciences Inc

Achieve Life Sciences shares climb following positive results from its smoking cessation study

Its plant-based compound cystine is meant to reduce nicotine withdrawal symptoms

Man breaking a cigarette in half
The Washington-based biotech develops smoking cessation aids

Achieve Life Sciences Inc (NASDAQ:ACHV) shares soared double digits following the announcement of positive clinical study results of its smoking cessation treatment.

The clinical-stage pharmaceutical company conducted a study looking into the effect of food on cystine’s bioavailability, which refers to the rate at which a drug is absorbed into the system.

Shares of the Washington-based biotech jumped nearly 38% to $3.76 in Thursday pre-market trading.

READ: Achieve Life Sciences shares rise on release of new plan for smoking cessation drug

The plant-based compound interacts with the brain’s nicotine receptors to reduce nicotine withdrawal symptoms.

The study took a look at the bioavailability of a new formulation of 3 mg of cystine in 12 healthy volunteer smokers under fed and fasted conditions.

The results showed that cystine was absorbed with maximum concentration levels observed in the blood within less than two hours, with or without food.

"We believe this new cytisine formulation will allow for an extended shelf-life and will be used in the upcoming Phase 2b clinical trial as well as the Phase 3 clinical program," said CEO Rick Stewart in the company’s press release.

Similar results were found in the study evaluating the previous cystine formulation in 24 healthy non-smoking volunteers.

Tobacco use is the leading cause of preventable death, responsible for nearly six million deaths annually worldwide, according to the World Health Organization’s Report on the Global Tobacco Epidemic.

Quick facts: Achieve Life Sciences Inc

Price: 0.5175 USD

NASDAQ:ACHV
Market: NASDAQ
Market Cap: $12.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: RPM Automotive announces key appointments and growth...

RPM Automotive Group Ltd (ASX:RPM) managing director Clive Finkelstein and newly appointed non-executive director Alex Goodman update Proactive on a number of key appointments to the board since the company listed on the ASX late year. The MD spoke about the key successes and challenges...

1 hour, 43 minutes ago

2 min read